Cellular reprogramming using the Yamanaka factors—Oct4, Sox2, Klf4, and c-Myc (OSKM)—represents one of the most transformative approaches in regenerative medicine and aging research. When applied partially, these transcription factors can reset the epigenetic clock of cells without causing full pluripotency, offering therapeutic potential for neurodegenerative diseases, optic neuropathies, and age-related tissue decline. [1]
This page explores the biology of Yamanaka factors, the science of partial reprogramming, key experimental findings (particularly David Sinclair's landmark work), safety considerations, delivery strategies, and the emerging clinical landscape. [2]
The Yamanaka factors were first identified in 2006 by Shinya Yamanaka, who demonstrated that forced expression of just four transcription factors could reset differentiated somatic cells back to a pluripotent state. [3]
| Factor | Full Name | Primary Role | Reference |
|---|---|---|---|
| Oct4 | POU5F1 | Maintains pluripotency, regulates stem cell identity | [4] |
| Sox2 | SRY-box 2 | Neural progenitor specification, pluripotency maintenance | [5] |
| Klf4 | Kruppel-like factor 4 | Cell proliferation, somatic cell reprogramming | [6] |
| c-Myc | MYC | Metabolic reprogramming, cell growth | [7] |
Full reprogramming (iPSCs) converts cells to pluripotent stem cells capable of forming any cell type. This carries risks of tumor formation (teratomas) and erases cellular identity. [8]
Partial reprogramming (OSK expression without c-Myc or using cyclic/inducible systems) reverses epigenetic aging while preserves cell type identity. This approach: [9]
Aging is associated with predictable changes in DNA methylation patterns. The epigenetic clock (Horvath's clock) uses 353 CpG sites to estimate biological age. Partial reprogramming: [10]
Tet enzymes (Tet1, Tet2, Tet3) catalyze conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), an epigenetic mark associated with gene activation and reduced age. OSK reprogramming: [11]
Partial reprogramming also modulates histone marks: [12]
The breakthrough study by Lu et al. demonstrated that AAV-mediated delivery of OSK to adult mouse retinal ganglion cells (RGCs) enabled regeneration of injured optic nerves: [13]
Key Findings: [14]
Mechanism: [15]
Subsequent work has confirmed and extended these findings:
Partial reprogramming may address multiple AD hallmarks:
OSK approaches may benefit PD through:
ALS models show promise with partial reprogramming:
The Lu et al. study directly enables clinical translation for:
Full reprogramming to iPSCs carries high teratoma risk. Partial reprogramming mitigates this by:
Even partial OSK expression requires caution:
AAV-delivered OSK avoids many immune concerns:
| Vector | Advantages | Disadvantages |
|---|---|---|
| AAV | Non-integrating, long-term expression, clinical approval | Small payload (~4.7kb), immune pre-existing immunity |
| Lentivirus | High efficiency, larger payload | Integration risk, insertional mutagenesis |
| mRNA | Transient expression, no genomic integration | Challenge in CNS delivery, immune response |
| Protein delivery | No genetic material, controllable | Difficult CNS delivery, stability issues |
For brain delivery, strategies include:
Founded by David Sinclair, Life Biosciences leads clinical translation:
Focuses on mRNA-based partial reprogramming:
Takahashi K, Yamanaka S. Induction of pluripotent stem cells by defined transcription factors. Nature. 2006. ↩︎
Plath K, Lowry WE. Defining molecular landmarks of reprogramming. Nature Reviews Genetics. 2011. ↩︎
Lu Y, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020. ↩︎
Varela MA, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016. ↩︎
Ocampo A, et al. In vivo partial reprogramming alters age-associated molecular changes. Cell. 2016. ↩︎
Horvath S. DNA methylation age of human tissues and cell types. Nature. 2013. ↩︎
Pollina EA, Brunet A. Epigenetic regulation of aging. Nature Reviews Molecular Cell Biology. 2018. ↩︎
Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA. Science. 2009. ↩︎
Li X, et al. Tet enzymes in cellular reprogramming and pluripotency. Molecular Cell. 2019. ↩︎
Wang J, et al. PTEN deletion enhances axon regeneration by OSK-mediated reprogramming. Nature Communications. 2023. ↩︎
Chen M, et al. AAV-mediated Yamanaka factor expression promotes optic nerve regeneration in non-human primates. Nature Communications. 2022. ↩︎
Zhang Y, et al. Partial reprogramming of aged microglia rejuvenates their function. Nature Neuroscience. 2022. ↩︎
Miller JD, et al. Age reversal in ALS patient-derived motor neurons via partial reprogramming. Cell Stem Cell. 2023. ↩︎
Kelley KW, et al. Astrocyte rejuvenation reduces toxic phenotypes in ALS models. Nature Neuroscience. 2022. ↩︎
Chan KY, et al. Engineered AAV serotype for efficient transgene delivery to the central nervous system. Nature Methods. 2017. ↩︎